High Court Pauses Limits on Mifepristone
The U.S. Supreme Court has temporarily blocked a 5/1 lower court ruling that would have curtailed access to the abortion pill mifepristone, preserving the current FDA regulatory framework while the justices consider emergency appeals. The administrative stay, issued by justice Samuel Alito, halts the U.S. Court of Appeals for the Fifth Circuit decision that would have reinstated in-person dispensing requirements and rolled back telehealth and mail distribution of the drug.
The case centers on FDA’s Risk Evaluation and Mitigation Strategy (REMS) for mifepristone and its removal of a long-standing in-person dispensing requirement in 2021, which allowed certified pharmacies to dispense the drug, a shift that enabled prescribing via telehealth and delivery by mail. Drug sponsors — including Danco Laboratories and GenBioPro — argue the 5th Circuit ruling would effectively override FDA’s scientific judgment and create immediate supply and compliance disruptions.
The underlying lawsuit, led by Republican-led states including Louisiana, challenges the legality of FDA’s regulatory changes and raises broader questions about judicial authority to second-guess agency decisions on drug safety and access.
In reaction to the lower court ruling, former FDA principal deputy commissioner Josh Sharfstein had this to say: “The 5th Circuit decision inappropriately interferes with the FDA's ability to establish policies for access to medical products based on evidence. The court has done more than undermine access to mifepristone; it has destabilized the regulatory system that supports the development of new products and the care of patients across the country.”
The Supreme Court’s action leaves current REMS conditions in place at least temporarily, maintaining nationwide access through pharmacies and telehealth channels. The order is procedural and does not address the merits, but it signals continued scrutiny of how far courts can go in revisiting FDA approvals and post-market regulatory decisions — an issue with potential implications well beyond abortion drugs. The temporary measure is set to remain in effect until at least 5/11
Mifepristone, typically used in combination with misoprostol, accounts for a majority of abortions in the U.S. and has become a central focus in legal battles following the Supreme Court’s 2022 decision overturning Roe v. Wade.
Meanwhile, FDA has said it will conduct an updated review of mifepristone’s safety and risk profile, amid the ongoing litigation and political scrutiny. The agency has emphasized that its prior decisions were grounded in extensive clinical data and post-market surveillance, but signaled it is prepared to reassess the evidence under its standard pharmacovigilance and REMS review authorities. The move could feed into both the legal fight and future regulatory decisions on labeling or distribution controls.